Soriot should explain the curious case of AstraZeneca’s non-deal

Sources

Coverage

Limited spectrum

Sentiment

0.00

◀ Left 100%Centre 0%Right 0% ▶

How we rate bias →

This story is currently only covered by one source from a single part of the political spectrum. NewsDeck will update this page automatically if other outlets pick up the story.

shopping_bagUK Politics & Current Affairs Books

Go deeper than the headlines with books from journalists and historians covering British politics.

Browse books on Amazonarrow_forward

NewsDeck Poll

Do you think this story is being covered fairly across the political spectrum?

Loading…

Left

(1)

Guardian Business

Soriot should explain the curious case of AstraZeneca’s non-deal

AstraZeneca’s rumoured takeover of Bristol Myers Squibb already looked weird, and was met with a lack of enthusiasm by shareholders Hold the heartburn pills. It seems AstraZeneca is no longer contemplating a takeover of US rival Bristol Myers Squibb (BMS) to create a $400bn (£300bn) pharmaceutical colossus. On Monday, the UK firm’s shares plunged 9% on the FT’s report of preliminary talks. On Wednesday, Reuters said…